Obesity
Conditions
Interventions
C Group:At 8pm the night before surgery and on the day after tracheal intubation, nebulized inhalation of 5ml of physiological saline was performed
PHC Group:At 8pm the night before surgery and after tracheal intubation on the day of surgery, nebulized inhalation of 0.5mg/5ml of pentachloroquine hydrochloride was administered
Sponsors
The First Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Part 1: Effects of nebulized inhalation of pentachloroquine hydrochloride on respiratory mechanics during laparoscopic surgery in obese patients 1. Age>=18 years old; 2. ASA (American Society of Anesthesiologists Classification) grades II-III; 3. Body mass index (BMI)>=30kg/m2; 4. Patients undergoing elective laparoscopic sleeve gastrectomy; 5. No history of drug allergies or abnormal anesthesia. Part 2: Study on the Effects and Mechanisms of Nebulized Inhalation of Pentachloroquine Hydrochloride on Postoperative Pulmonary Function in Obese Patients Undergoing Laparoscopic Surgery 1. Age range: 18 to 65 years old; 2. ASA (American Society of Anesthesiologists Classification) grades II-III; 3. Body mass index (BMI)>=30kg/m^2; 4. Patients who undergo gynecological and gastrointestinal laparoscopic surgery at a scheduled time, with a duration of less than 2 hours of pneumoperitoneum; 5. No history of drug allergies or abnormal anesthesia.
Exclusion criteria
Exclusion criteria: Part 1: Effects of nebulized inhalation of pentachloroquine hydrochloride on respiratory mechanics during laparoscopic surgery in obese patients 1. Patients with a history of ALI/ARDS within 3 months, severe pulmonary dysfunction (SpO2=3), or rapid arrhythmia within 3.1 years; 4. Severe liver and kidney dysfunction (requiring renal replacement therapy, Child Pugh C grade); 5. Moderate to severe symptomatic prostate enlargement or narrow angle glaucoma; 6. Patients who have used inhaled ß 2 receptor agonists, anticholinergic drugs, and/or glucocorticoids within one month prior to surgery; 7. Patients who have participated in other drug trials within one month prior to surgery; 8. Patients who are unable to cooperate with inhalation therapy; 9. Individuals who are known to be allergic to pentachloroquine hydrochloride; 10. Refuse to join clinical trials. Part 2: Study on the Effects and Mechanisms of Nebulized Inhalation of Pentachloroquine Hydrochloride on Postoperative Pulmonary Function in Obese Patients Undergoing Laparoscopic Surgery 1.Patients with a history of ALI/ARDS within 1.3 months, severe pulmonary dysfunction (SpO2=3), or rapid arrhythmia within 3.1 years; 4. Severe liver and kidney dysfunction (requiring renal replacement therapy, Child Pugh C grade); 5. Moderate to severe symptomatic prostate enlargement or narrow angle glaucoma; 6. Patients who have used inhaled ß 2 receptor agonists, anticholinergic drugs, and/or glucocorticoids within one month prior to surgery; 7. Patients who have participated in other drug trials within one month prior to surgery; 8. Patients who are unable to cooperate with inhalation therapy; 9. Individuals who are known to be allergic to pentachloroquine hydrochloride; 10. Refuse to join clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the driving pressure (DP) curve (ArAUC).;The incidence of atelectasis; | — |
Secondary
| Measure | Time frame |
|---|---|
| General condition of the patient;Airway peak pressure;Area under the airway peak pressure curve;Dynamic lung compliance ;Area under dynamic lung compliance curve;Drive pressure;Alveolar arterial oxygen pressure difference (A-aO2);oxygenation index;Serum SP-A;The incidence of postoperative 48 hour hypoxemia;Incidence of atelectasis;Pulmonary ultrasound score;Adverse reaction occurrence;Pulmonary ultrasound score;oxygenation index;Alveolar arterial oxygen pressure difference (A-aO2);Airway peak pressure;Area under the airway peak pressure curve;Dynamic lung compliance ;Area under dynamic lung compliance curve;Drive pressure;Area under the driving pressure curve; IL-8 ;IL-1 ß;SP-A;MPO-DNA;NLRP3;CitH3;CC16 ;Global Heterogeneity Index (GI);Ventilation center area;Dorsal ventilation ratio;Minimum oxygenation index;SpO2 < 92% cumulative time;Incidence of atelectasis;Pain Scale (VAS);Analgesic medication dosage; | — |
Countries
China
Contacts
Public ContactGuo Qiongmei
The First Hospital of Hebei Medical University
Outcome results
None listed